About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Please ensure Javascript is enabled for purposes of
website accessibility
About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact